One of the first questions people ask when considering GLP-1 therapy is simple: how long until I see results?
The honest answer is that it depends, but there is a well-established timeline that most patients follow. Understanding it will set realistic expectations, help you interpret what is happening in the early weeks, and keep you on track when progress feels slower than expected.
Weeks 1-2: Appetite Suppression Begins
Most patients notice a meaningful reduction in appetite within the first one to two weeks, even at the starting (lowest) dose. You may find that you feel satisfied with smaller portions, stop thinking about food between meals, or simply feel less driven by cravings.
Some patients also experience mild side effects during this phase: nausea, loose stools, or fatigue. These are normal responses to the peptide and typically settle over the following weeks as the body adjusts.
Weight loss at this stage: 0 to 2 kg. The scale may not move dramatically yet, but physiological changes are already underway at a cellular level.
Weeks 4-8: First Measurable Results
By weeks four to eight, most patients are seeing 3 to 6 percent of total body weight lost. At 90 kg, that is 2.7 to 5.4 kg of fat loss, often visible in the face, abdomen, and waist.
The dose is typically increased at the four-week mark if tolerated well. This titration step is where results begin to accelerate.
Metabolic markers begin to improve: fasting glucose drops, post-meal blood sugar spikes flatten, and energy levels often increase noticeably.
Months 3-6: Momentum Builds
This is the phase where most patients report the most dramatic visible changes. Monthly weight loss of 2 to 4 kg becomes consistent. By month six, average total weight loss across clinical studies is 10 to 14 percent of starting body weight.
This is also when meaningful improvements show up in your biomarkers: triglycerides drop, HDL cholesterol improves, blood pressure may fall, and markers of liver health typically normalise.
Months 6-12: Approaching Target Weight
By the 12-month mark, many patients have reached 15 to 20 percent total weight loss, or more with tirzepatide. Appetite suppression is fully established, and most have adapted comfortably to the injection routine.
The dose is typically held steady at the maximum tolerated level during this phase. The focus shifts from acceleration to sustainable progress and long-term metabolic optimisation.
What Affects Your Individual Timeline?
Several factors influence how quickly you respond:
- Starting BMI: Higher baseline weight tends to produce faster absolute weight numbers early on
- Metabolic health: Insulin resistance can slow early response but typically improves progressively with the peptide
- Dose level: Adequate titration to the therapeutic dose is essential for maximum efficacy
- Lifestyle: GLP-1 works best alongside a moderate caloric deficit and adequate protein intake to preserve muscle mass
- Peptide choice: Tirzepatide tends to produce faster and greater results than semaglutide at equivalent timepoints
Why Biomarker Tracking Matters Beyond the Scale
Weight is a crude proxy for metabolic health. At Longegra, we track HbA1c, fasting insulin, liver enzymes, lipids, and other markers alongside body composition so you can see the full picture of what is changing inside your body, not just the number on the scale.
Many patients are surprised to find that their metabolic markers improve significantly before dramatic visible weight loss. This is evidence the therapy is working at a cellular level, even when the scale is slow.
Frequently Asked Questions (FAQs)
If you are not losing weight after 12 weeks at an adequate dose, a physician review is warranted. Common reasons include insufficient dose, subtherapeutic peptide quality, or an underlying metabolic issue such as untreated hypothyroidism or significant insulin resistance. At Longegra, we investigate non-response with updated biomarker testing and adjust protocols accordingly.
